BRAF and melanoma: We tested the ability of PLX4032 to differentially block MAPK pathway signaling in a panel of human melanoma cell lines (Table 1) by quantitating the inhibition of phosphorylated Erk (pErk), a downstream target of B-Raf activity, using intracellular phosphospecific flow cytometry (Figure 1A).